Premium
Drug Delivery: Heparin‐Coated Albumin Nanoparticles for Drug Combination in Targeting Inflamed Intestine (Adv. Healthcare Mater. 16/2020)
Author(s) -
Zhang Sufeng,
Cho Won Joon,
Jin Amy T.,
Kok Lie Yun,
Shi Yunhua,
Heller David E.,
Lee YoungAh Lucy,
Zhou Yixuan,
Xie Xi,
Korzenik Joshua R.,
Lennerz Jochen K.,
Traverso Giovanni
Publication year - 2020
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.202070052
Subject(s) - in vivo , drug , targeted drug delivery , drug delivery , inflammatory bowel disease , heparin , albumin , inflammation , pharmacology , medicine , colitis , in vitro , chemistry , immunology , disease , materials science , pathology , nanotechnology , biology , biochemistry , microbiology and biotechnology
Targeting areas of inflammation stands to transform the capacity to effectively treat inflammatory bowel disease while minimizing systemic side effects. In article number 2000536, Giovanni Traverso and co‐workers describe heparin‐coated human serum albumin nanoparticles that can encapsulate drug combination, suppress inflammation in macrophages in vitro, and selectively bind to inflamed intestine in vivo in a murine model of acute colitis.